NSNicolas W. Shammas

Nicolas W. Shammas

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Nicolas W. Shammas has a total of 509 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Corrigendum to “Safety and Effectiveness of the SantrevaTM-ATK Endovascular Revascularization Catheter in the RESTOR-1 Peripheral CTO Crossing Pivotal Study” [The American Journal of Cardiology 263 (2026)33−42]

    by Subhash Banerjee, Christopher Metzger, Mallik Thatipelli, Venkatesh G. Ramaiah, Sameh Sayfo, Tony Das, Shirling Tsai, Omar Hyder, Nicolas W. Shammas, Matthew Bunte, et al.

  • Predictors of Use of Pharmacomechanical Therapies versus Standard Therapy in Intermediate-Risk Pulmonary Embolism: A Retrospective Study from Two Medical Centers

    by Nicolas W. Shammas, William Sharis, Gail A. Shammas, Sue Jones-Miller

    Pharmacomechanical therapy (PMT) is increasingly used in patients with intermediate-risk pulmonary embolism (PE), but the clinical and anatomic factors associated with operator selection of PMT rather than standard anticoagulation remain incompletely characterized. We retrospectively analyzed 202 consecutive patients with intermediate-risk PE defined for this study by right ventricular dysfunction (right ventricle [RV]/left ventricle [LV] ratio > 0.9) and positive troponin. Ninety-seven patients underwent PMT with mechanical thrombectomy or catheter-directed thrombolysis, and 105 received standard therapy. Baseline characteristics, hemodynamics, PE distribution, and 30-day events were extracted. A multivariable binary logistic regression model was developed to identify factors associated with PMT selection, with internal validation using a 70/30 training–test split. Patients selected for PMT differed substantially from controls at baseline, including higher admission heart rate, higher pulmonary artery pressure, higher RV/LV ratio, lower systolic blood pressure, and a greater frequency of saddle PE. Concurrent deep vein thrombosis was documented in 0/97 PMT patients and 44/105 controls (p < 0.0001). In multivariable analysis, admission heart rate (odds ratio [OR] 1.0315, 95% confidence interval [CI] 1.0051–1.0585; p = 0.019), pulmonary artery pressure (OR 1.0438, 95% CI 1.0103–1.0785; p = 0.010), and PE distribution as a multilevel factor (overall p = 0.019) were associated with PMT selection. Training and test areas under the curve were 0.8049 and 0.8307, respectively. Thirty-day mortality was 5/97 (5.2%) in the PMT group and 5/105 (4.8%) in controls; serious bleeding from procedure to discharge occurred in 7/97 (7.2%) and 2/105 (1.9%), respectively. These event data are descriptive and were not adjusted for treatment selection bias. In this retrospective two-center cohort, higher admission heart rate, higher pulmonary artery pressure, and PE distribution were associated with operator selection of PMT. The model showed good discrimination in internal training and test datasets. Because treatment was not randomized and important baseline imbalances were present, observed clinical outcomes should be considered descriptive and should not be interpreted as evidence of comparative efficacy or safety of PMT versus standard therapy.

  • Open Access

    Treatment of Calcified Peripheral Artery Disease With the Shockwave Forward Peripheral Intravascular Lithotripsy System: One-Year Outcomes From the FORWARD PAD IDE and Mini S Feasibility Studies

    by Andrew Holden, John D. Corl, Sameh Sayfo, Bibombe P. Mwipatayi, Manar Khashram, Nicolas W. Shammas, Anderson Mehrle, Anvar Babaev, Peter A. Soukas, Richard Pin, et al.

  • Open Access

    Long-Term Efficacy of Lutonix in a Real-World Femoropopliteal Patients With Peripheral Arterial Disease: Insights From the SAFE-DCB US Registry

    by Nicolas W. Shammas, Dion Franga, Erin Moore, George Mueller, Thomas P. Davis, Edward Woo

    Background: Several studies have demonstrated the efficacy of paclitaxel drug-coated balloons (DCBs) for the treatment of femoropopliteal (FP) lesions in patients with peripheral artery disease (PAD). Despite the available evidence, long-term real-world efficacy data are limited. Objectives: To report the 3-year outcomes of the prospective, multicenter, single-arm real-world registry conducted in the United States, assessing the clinical use of the Lutonix 035 DCB in arteries of the superficial femoral artery (SFA) and popliteal artery (PA). Methods: In the SAFE-DCB US Registry, a total of 1005 subjects at 74 investigational sites were treated with the Lutonix 035 DCB and were followed up to 36 months. The per protocol included 966 patients (mean age 69.1 years; 56.7% male). A total of 1237 target lesions were treated, in which 93.3% were de novo, 85.2% were located in the SFA, and 88% had mild-to-severe calcification. Forty-five percent of the patients were Rutherford 3, and 35.1% had critical limb-threatening ischemia. The primary efficacy endpoint is target lesion revascularization (TLR) at 12 months. Secondary endpoints included rate of primary patency at 12 months and freedom from TLR and freedom from target vessel revascularization (TVR) evaluated through 36 months. The safety endpoints evaluated through 36 months were freedom from the composite of device- and/or procedure-related perioperative (≤30 day) death, TVR, and freedom from major amputation of the target limb. Results: Primary patency at 12 months post-index procedure by Kaplan-Meier estimates was 83.7%. Freedom from TLR at 12 months was 88.6%, 75.7% at 24 months, and 74.4% at 36 months. At 36 months, freedom from TVR post-index procedure by Kaplan-Meier estimates was 69.5%. Freedom from primary safety events at 30 days was 98.2%. Freedom from composite of all-cause perioperative (≤30 day) death and from the following: index limb amputation, index limb reintervention, and index-limb-related death by Kaplan-Meier estimates at 12 months was 80.8%, at 24 months 67.4% and 58.4% at 36 months. Freedom from major amputation of the target limb at 36 months was 95.6%. Conclusion: The results from the SAFE-DCB US Registry for femoral popliteal (FP) disease demonstrated sustained safety and efficacy over 3 years following the Lutonix 035 DCB intervention. Clinical Impact: This prospective real-world population study supports long-term clinical outcomes of Lutonix and provides meaningful insights into the sustained efficacy of drug-coated balloon (DCB) therapy in real-world femoropopliteal population. The low-bailout stenting rate (1.7%), and the 36-month sustained Freedom from target lesion revascularization rate (74.4%) supporting DCB usage when a “leave nothing behind” approach is favored. Furthermore, these results reinforce the effectiveness of DCBs in the endovascular treatment peripheral artery disease.

  • Sex Differences in Peripheral Arterial Disease: Presentation, Treatment, and Outcomes

    by Nicolas W. Shammas

    To summarize current evidence on sex-related differences in peripheral arterial disease (PAD) with respect to risk factors, disease distribution, response to endovascular therapy, and surgical outcomes. This review synthesizes data from observational studies, registries, and randomized trials evaluating sex-based differences in PAD epidemiology, anatomy, treatment patterns, and clinical outcomes. Women with PAD typically present at an older age and have a higher prevalence of comorbidities, including diabetes, chronic kidney disease, anemia, and frailty. They are less likely to receive guideline-directed medical therapy and more frequently present with atypical symptoms, contributing to delayed diagnosis and higher rates of chronic limb-threatening ischemia. Anatomically, women exhibit smaller vessel diameters, more diffuse and distal disease, and greater lesion complexity. Endovascular therapy yields similar or lower rates of major amputation in women compared with men; however, women experience higher rates of repeat revascularization and periprocedural complications, likely related to vessel size and comorbidity burden. In surgical revascularization, historical disparities in outcomes have diminished, with contemporary data demonstrating comparable limb salvage rates, although women may still experience longer hospital stays and higher wound complication rates. Sex differences in PAD significantly impact clinical presentation, anatomical patterns, and treatment outcomes. Women present later with more advanced disease yet achieve similar or improved limb salvage compared with men. These findings underscore the need for earlier diagnosis, equitable medical therapy, and individualized treatment strategies. Future studies should incorporate sex-specific analyses to optimize PAD management and improve outcomes across populations.


  • Three-Year Outcomes of the Auryon Laser Atherectomy System in Treating Infrainguinal Peripheral Arterial Disease: A Single-Center Experience

    by Nicolas W. Shammas, Gail A. Shammas, Yisroel Tannenbaum, Allie Abbott, Amrita Bahia, Susan Jones-Miller, Venkat Shankarraman

    The Auryon 355-nm laser atherectomy system (AngioDynamics, Inc., Latham, NY) showed a high rate of freedom from target lesion revascularization (TLR) at 1-year follow-up. Long-term data for the Auryon laser are not available. In this study, we present the 3-year outcome of the Auryon SCE study on TLR in all comers at a single center. The Auryon SCE was a single-center retrospective study that evaluated the outcome of consecutive patients treated with the Auryon laser for infrainguinal arterial disease. TLR rates were obtained from medical records review. Secondary endpoints included unplanned major amputation and total mortality. Kaplan–Meier survival analysis was performed to estimate the freedom from TLR following index procedure. A total of 56 patients (65 procedures, 70 lesions) were enrolled. The mean age was 70.9 years, 48.2% diabetics, and 25% with limb ischemia. Of the 70 lesions, 31.4% had severe calcification, 38.6% were chronic total occlusions, and 48.6% were de novo disease (in-stent restenosis 29.6%). Stenting was performed in 24/70 (34.3%) lesions (11/70, 15.7% were bailout). The majority of treated lesions were femoropopliteal (90.0%). At 3 years, mortality occurred in 9/56 (16.1%) patients and major amputation 3/47 (6.4%). The probability of freedom from TLR was 65.3%. At baseline, 69.6 and 25% had severe claudication and chronic limb-threatening ischemia versus 5 and 5% at 3 years, respectively. The Auryon laser had an acceptable freedom from TLR at 3 years with sustained significant improvement in Rutherford Becker categories.

  • Shockwave Lithoplasty versus 355-nm Laser for Vessel Preparation in Calcified Femoropopliteal Arterial Disease: A Single-Center Comparative Study

    by Nicolas W. Shammas, Yisroel Tannenbaum, Waheeb John Shammas, Allie Abbott, Gail A. Shammas, Amit Bahia, Sue Jones-Miller, Venkat Shankarraman

    Comparative data on vessel preparation using intravascular Shockwave lithotripsy (Johnson and Johnson, New Brunswick, NJ) or the 355-nm Auryon laser (Angiodynamics, Latham, NY) in calcified femoropopliteal arterial disease is limited. This is a retrospective, single-center study evaluating the 30-day safety and effectiveness of the 355-nm laser system versus Shockwave lithotripsy in treating calcified femoropopliteal arterial disease. Angiographic images were reviewed by core laboratory. The primary endpoint of safety is freedom from major adverse limb event (MALE) at 1 month. The primary effectiveness endpoint is acute procedural success, defined as achieving less or equal 30% mean residual narrowing postfinal treatment with no bailout stenting. A total of 29 consecutive patients were included (355-nm laser 15 patients [15 vessels] and Shockwave lithoplasty 14 patients [15 vessels]). At baseline, there were no differences between the two cohorts in demographics or clinical presentation. Also, there were no difference in total occlusions (33.3 vs. 33.3%), lesion length (median: 12.0 vs. 12.1 cm), presence of moderate to severe calcium (86.7 vs. 100%). At 30-day, there were no MALEs in both groups. There were no perforations, type D dissections, or distal embolization seen in both cohorts. Bailout stent was driven by a higher residual stenosis and was 35.7 vs. 13.3% in Shockwave versus laser, respectively (p = 0.215). At 30-day ankle–brachial indices were similar between the two groups (median: 0.9 vs. 1.09). Both Shockwave and 355-nm laser are effective and safe in calcified femoropopliteal lesions. A numerically higher rate of bailout stenting was seen with Shockwave lithoplasty.

  • Advances in Endovascular Therapy for Infrainguinal Peripheral Arterial Disease: Devices and Outcomes

    by Nicolas W. Shammas

    The management of infrainguinal peripheral arterial disease (PAD) has undergone a remarkable transformation over the past two decades, driven by rapid innovation in drug delivery systems, plaque-modifying technologies, intravascular imaging, and minimally invasive bypass alternatives. This review summarizes contemporary advances in endovascular therapy and highlights the clinical evidence supporting each major device category. Drug-coated balloons and drug-eluting stents remain foundational technologies in treating PAD. Paclitaxel-coated platforms have demonstrated durable reductions in target lesion revascularization in multiple randomized trials, while sirolimus-based devices have recently emerged as viable alternatives. The LIFE-BTK trial established the first everolimus-eluting scaffold with proven improvements in restenosis among patients with chronic limb-threatening ischemia. Equally transformative has been the evolution of lesion-preparation strategies. Atherectomy, scoring balloons, and intravascular lithotripsy (IVL) have improved vessel compliance, reduced recoil, and optimized drug uptake, particularly in heavily calcified lesions. Among these, IVL has gained rapid global adoption due to its safety profile and ability to modify deep calcium using low-pressure balloon inflation. The 355-nm laser and contemporary orbital atherectomy systems have expanded treatment options for complex, long, calcified, and below-the-knee lesions. Intravascular ultrasound (IVUS) consistently outperforms angiography in vessel sizing, dissection detection, and optimization of stent deployment. Multiple large registries and randomized trials have demonstrated significant improvements in patency, limb salvage, and clinical outcomes with IVUS-guided therapy. Finally, the fully percutaneous DETOUR bypass system offers a novel alternative for patients with long-segment femoropopliteal occlusions who are poor surgical candidates. This stent-based bypass technique has shown promising mid-term patency, high limb salvage rates, and low deep-vein thrombosis incidence. Collectively, these advances underscore the importance of individualized, multimodal endovascular therapy that aims to leave the least amount of metal behind while maintaining good long-term outcomes. Ongoing randomized trials and long-term data will continue to sharpen best practices and define the optimal role of each technology in treating complex PAD.

  • Five-Year Outcome of the Venovo Venous Stent for the Treatment of Iliac Vein Compression: Results from a Single Center

    by Abdullah Ayyoub, Nicolas W. Shammas, Gail A. Shammas, Sue Jones-Mller

    The Venovo self-expanding venous stent (Bard/BD, New Jersey, United States) is approved for the treatment of symptomatic iliofemoral venous obstruction and demonstrated excellent 3-year outcomes in the pivotal VERNACULAR trial. Long-term (>3-year) data remain limited. This retrospective, single-center study evaluated 50 consecutive patients who completed 5-year follow-up after receiving the Venovo stent for symptomatic iliac vein compression. Data were extracted from medical records following approval by a central ethics committee. Of the 50 patients, 6 died and 1 was lost to follow-up. The primary endpoint was major adverse events at 5 years, including target lesion revascularization (TLR), target vessel revascularization (TVR), and mortality. Secondary analyses assessed changes in CEAP class, edema, and active ulceration compared with baseline. No TLR or TVR occurred during the 5-year follow-up. Six deaths were observed, none procedural or device-related. Overall survival was 87.8%. Duplex ultrasound demonstrated 100% patency. CEAP class significantly improved from baseline to 5 years (p = 0.0011), driven primarily by reduced edema and ulcer resolution. The Venovo venous stent demonstrated excellent long-term safety with 100% patency and no TLR at 5 years. Clinical improvement, including reduced edema and sustained ulcer healing, persisted throughout follow-up.